The Conference Forum today announced the launch of the 12th annual Immuno-Oncology 360º Summit (IO360°) taking place February 10-12, 2026, at the Sheraton Boston Hotel in Boston, MA.
The IO360° 2026 VIP All-Star Lineup includes:
- Dr Jedd Wolchok, Meyer Director of the Sandra and Edward Meyer Cancer Center and Professor of Medicine, Weill Cornell Medicine on charting the next era of immuno-oncology from checkpoint blockade and beyond
- Dr Miriam Merad, Chair, Department of Immunology and Immunotherapy, Director, Marc and Jennifer Lipschultz Precision Immunology Institute, Director, Mount Sinai Human Immune Monitoring Center, Mount Sinai School of Medicine, on targeting myeloid cells for therapeutic enhancement
- Dr Andrea Cercek, Physician-Scientist & Medical Oncologist; Section Head of Colorectal Cancer; Founder and co-director of the Center for Young Onset Colorectal and Gastrointestinal Cancer, Memorial Sloan Kettering Cancer Center, on the evolving insights and next steps from the landmark dostarlimab trial
- Dr Ira Mellman, President of Research, Parker Institute for Cancer Immunotherapy (PICI), on the scientific and clinical trajectory of immuno-oncology and what the next chapter could look like
- Dr Andrew Baum, Chief Strategy and Innovation Officer, Pfizer, on strategic innovations and industry trends
“IO360º provides curated content on the most pertinent scientific and clinical advances in IO paired with business and market insights highlighting critical trends and directions of the field, in a unique blend that makes this event deeply insightful and predictive of the future of IO,” said Dr Axel Hoos, former CEO of Scorpion Therapeutics and founding advisor of IO360º.
The 2026 key topic areas include:
- Biomarkers/Assay Development
- Business and Investing Aspects
- Discovery/Preclinical
- Autoimmune Disease & IO
- ADCs & IO
- IO Combinations
- Translational Science
- Imaging Advancements
- Cell Therapy
- Neoadjuvant/Adjuvant
- Clinical Developments
“Through 100+ multi-dimensional talks, cutting-edge presentations, future-focused panel discussions and built-in networking, IO360º continues to deliver an environment for building impactful collaborations between trailblazers in translational science, innovators in clinical development, and pioneers in investment and business development, to advance cancer treatments,” said Kate Woda, Director of IO360º.
The 2026 meeting includes top leadership in translational science and clinical development, transformational biology, investment and business development and clinical operations from the following organizations:
- AbbVie
- Abingworth
- Amgen
- Astellas Pharma
- AstraZeneca
- Avidity Partners
- Bayer Oncology
- BioNTech
- BMS
- Boehringer Ingelheim
- City of Hope
- Daichii-Sankyo
- Fred Hutchinson Cancer Center
- Invus Group
- Janssen
- Kite Pharma
- Memorial Sloan Kettering Cancer Center
- Merck
- Moderna
- Morgan Stanley
- Mount Sinai
- MPM BioImpact
- NCI
- Novartis
- OrbiMed
- RA Capital
- Regeneron
- Stanford University
- Stifel
- Takeda
To learn more about IO360, visit io360summit.com.
